Yael N. Kusne, M.D., Ph.D.

Open

• Clonal Hematopoiesis (CH) and Hematological Toxicity after Radiotheranostic Agents in Solid Tumor Patients (CHIP) Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

  The overall objective of this project is to combine robust clinical data (e.g. prior chemotherapy or radiation exposure, cumulative radiotheranostic dose) with geneticclonal abnormalities (blood-based CHIP panel) in studying the predisposing risk factors for developing hematological toxicity including t-MN in radiotheranostic treated solid tumor patients.